I am of the opinion these type of numbers are at best only a guideline. If cobroxin is not addictive and weans the user into lower dosages and eventually no usage when not in pain, then we realistically have to margin the numbers for those reasons.
Afterall...addiction creates sales, in many different ways.
However, that being said, a product with no addictive properties, all natural ingredients, and one that actually works on the pain itself will no doubt have an adverse impact on the market as compared to analgesics/opiates. in my opinion.
Users who cannot or choose to not use opiates for the many and varied reasons inherent in them, will now have an alternative product to use when required.
Precisely to what magnitude this could affect cobroxin sales in comparison to the reduced"margined" sales, i have no idea.
For certain the product should invade the market share nicely enough and impregante the drug reps mind's to the degree necessary to effect a very nice growth pattern in the early years.
I would think cobroxin has a healthy head start on any competing substances.
NO FEAR
Market Data 
Markets 
AI
